Grace Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Grace Therapeutics, Inc. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from 2019 to 2023.
  • Grace Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending June 30, 2023 was $0.000, a 100% decline year-over-year.
  • Grace Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $7.36M, a 2321% increase from 2022.
  • Grace Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $304K.
  • Grace Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $0.000, a 100% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $7.36M +$7.06M +2321% Apr 1, 2023 Mar 31, 2024 10-K 2024-06-21
2022 $304K +$304K Apr 1, 2022 Mar 31, 2023 10-K 2024-06-21
2021 $0 -$59.5M -100% Apr 1, 2021 Mar 31, 2022 10-K 2023-06-23
2020 $59.5M +$46.3M +351% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-21
2019 $13.2M Apr 1, 2019 Mar 31, 2020 10-K 2021-06-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.